Entering text into the input field will update the search result below

Otonomy's (OTIC) CEO David Weber on Q4 2017 Results - Earnings Call Transcript

Mar. 08, 2018 11:17 PM ETOtonomy, Inc. (OTIC)1 Comment
SA Transcripts profile picture
SA Transcripts

Otonomy (OTCPK:OTIC) Q4 2017 Earnings Conference Call March 8, 2018 4:30 PM ET


Laurence Watts - IR

David Weber - President and CEO

Paul Cayer - CFO and CBO

Kathie Bishop - CSO


Charles Duncan - Piper Jaffray


Good day, ladies and gentlemen and thank you for standing by. Welcome to the Otonomy Incorporated Fourth Quarter 2017 Earnings Conference. At this time, all participants are in a listen-only mode to prevent background noise. [Operator Instructions]

And now I would like to welcome and turn the call to Laurence Watts with Westwicke Partners.

Laurence Watts

Good afternoon and welcome to Otonomy's fourth quarter and full year 2017 financial results and business update conference call. Joining me on the call from Otonomy are Dr. David Weber, President and Chief Executive Officer; Paul Cayer, Chief Financial and Business Officer and Dr. Kathie Bishop, Chief Scientific Officer.

Before I turn the call over to Dr. Weber, I would like to remind you that today's call will include forward-looking statements based on current expectations. Such statements represent management's judgment as of today, and may involve risks and uncertainties that could cause actual results to differ materially from expected results.

Such statements include, but are not limited to, the acute otitis externa market opportunity for OTIPRIO, timing of Phase 3 clinical trial for OTIVIDEX in Ménière’s Disease, expectations regarding OTIVIDEX clinical trial design, timing of a Phase 1/2 clinical trial for OTO-413, timing of candidate selection for OTO-5XX and OTO-6XX programs, timing of a phase 1/2 clinical trial for OTO-313, the company’s expectations regarding its commercial partnering options for OTIPRIO, including divestiture, expected cost savings from discontinuation of OTIPRIO promotional support, expectations regarding value creating milestones, having resources to advance our product pipeline and the financial guidance for 2018.

Please refer to Otonomy's

Recommended For You

Comments (1)

Arnold Layne profile picture
Thanks for your work, Otonomy- from a former Meniere's and current tinnitus sufferer- and investor. Cheers and good luck.
To report an error in this transcript, .Contact us to add your company to our coverage or use transcripts in your business. Learn more about Seeking Alpha transcripts here. Your feedback matters to us!
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.